Cellebrite Appoints Shiven Ramji Chief Executive Officer, Succeeding Thomas E. Hogan
Rhea-AI Summary
Cellebrite (NASDAQ: CLBT) appointed Shiven Ramji as Chief Executive Officer, succeeding Thomas E. Hogan in a planned transition effective immediately. Ramji, who joined as President, Products and Technology in May 2026, will also join the Board of Directors.
For Q2 2026, Cellebrite reported ARR of $507.8 million (up 21% year-over-year) and revenue of $131.1 million (up 16% year-over-year). Subscription revenue reached $119.5 million, also up 16%. GAAP net income was $6.4 million and non-GAAP net income was $29.7 million. Adjusted EBITDA was $31.8 million with a 24.2% margin, and trailing twelve-month free cash flow was $144.2 million (28.0% margin).
The company cited longer sales cycles and lower-than-expected Inseyets expansions, leading to lowered full-year 2026 ARR and revenue outlook, now targeting ARR of $550–$560 million and revenue of $555–$561 million. At the same time, Cellebrite raised its 2026 adjusted EBITDA target to $153–$159 million (around 28% margin), reflecting continued operating discipline.
Positive
- ARR $507.8M, up 21% year-over-year in Q2 2026
- Revenue $131.1M, growing 16% year-over-year in Q2 2026
- Adjusted EBITDA $31.8M with a 24.2% margin in Q2 2026
- TTM free cash flow $144.2M, representing a 28.0% margin
- 2026 adjusted EBITDA guidance raised to $153M–$159M (~28% margin)
- FedRAMP High-based Guardian win and early monetization of Genesis AI solution
Negative
- Full-year 2026 ARR outlook reduced to $550M–$560M (14%–16% growth)
- Full-year 2026 revenue guidance lowered to $555M–$561M (17%–18% growth)
- Q2 ARR below internal expectations due to longer sales cycles and slower Inseyets expansions
Market Reaction – CLBT
Following this news, CLBT has declined 22.89%, reflecting a significant negative market reaction. Argus tracked a trough of -23.9% from its starting point during tracking. Our momentum scanner has triggered 33 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $11.76. Trading volume is exceptionally heavy at 93.4x the average, suggesting significant selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company Reports Second-Quarter 2026 Results; Company Lowers Full-Year 2026 ARR and Revenue Outlook and Raises Adjusted EBITDA Target
Adam Clammer, Chairman of Cellebrite's Board of Directors, stated, "We are deeply grateful to Tom for his extensive contributions to Cellebrite's success over the last three years. One of Tom's most important contributions was building a world-class team. Shiv's succession is the clearest proof of his success in this endeavor. With a product-first approach and a successful track record of building and growing businesses, Shiv is the right CEO for our next chapter. The Board has every confidence in Shiv and the management team."
Thomas E. Hogan commented, "It has been a privilege to lead Cellebrite – a company that truly makes the world a safer place. Over the past three years, we have navigated significant change while elevating our value proposition by broadening our solutions through a combination of organic innovation and M&A. With that foundation in place, Cellebrite's next chapter requires a world-class product and technology executive, and Shiv is exactly that leader. Given the long-term opportunity in front of Cellebrite, I have full confidence that Shiv and this team will build on our progress to address the expanding needs of our customers around the world. I want to thank Cellebrite's employees for their dedication, and our customers and shareholders for their trust. Cellebrite's future is very bright."
Shiv Ramji, Cellebrite's CEO, stated, "I am honored to lead Cellebrite at an important moment for the Company. Over my first three months, I have spent significant time with our customers, employees and leaders across the business, and I have come away with strong conviction in both the opportunity ahead and the work required to realize it. Our mission has never been more relevant: helping customers accelerate investigations, uncover trusted intelligence, deliver justice and protect communities."
Cellebrite Reports Second-Quarter 2026 Results
Cellebrite also announced today its financial results for the three and six months ending June 30, 2026.
Second-Quarter 2026 Financial Highlights
- Total Annual Recurring Revenue (ARR) of
$507.8 million 21% year-over-year - Recurring revenue dollar-based net retention rate of
117% , up 2 pts. over Q1 - Revenue of
$131.1 million 16% year-over-year - Subscription revenue was
$119.5 million 16% - GAAP gross profit and gross margin of
$105.9 million 80.8% , respectively; Non-GAAP gross profit and gross profit margin of$112.1 million 85.5% , respectively - GAAP net income of
$6.4 million $29.7 million - GAAP diluted earnings per share of
$0.02 $0.11 - Adjusted EBITDA and Adjusted EBITDA margin of
$31.8 million 24.2% , respectively - Free cash flow for the trailing twelve months of
$144.2 million 28.0% on a margin
"We delivered healthy second-quarter growth in
Ramji continued, "We are making tangible progress with our newer products, which further supports our confidence in the long-term opportunity. At the same time, we are taking a more measured view of that contribution in the near term, given elongated sales cycles and the timing of additional new product introductions anticipated for later this year."
Ramji concluded, "Given these dynamics, in combination with the pace and magnitude of Inseyets expansions, we have lowered our FY26 ARR and revenue outlook. We believe resetting expectations now is the responsible approach and provides a more appropriate foundation from which to execute. At the same time, continued operating discipline has enabled us to raise our FY26 adjusted EBITDA target."
Recent Business Highlights
Innovation
- Genesis Momentum: Cellebrite Genesis, the Company's purpose-built agentic AI solution, has continued to build momentum since its official launch on June 10th. Cellebrite achieved early monetization for Genesis in the second quarter. Since the start of the third quarter, the Company has continued to make further progress with Genesis adoption and related product enhancements.
- New Product Adoption: In addition to Genesis, Cellebrite has continued to see customer adoption build for new offerings introduced since the start of this year, namely its Guardian Investigate, CFID for drone forensics and Advanced Unlocks.
- Signature FedRAMP Win: Cellebrite also recently signed its first significant FedRAMP deal for Guardian, its SaaS-based evidence management solution delivered through the Cellebrite Government Cloud (CGC). In May 2026, Cellebrite announced that its Cellebrite Government Cloud (CGC) platform achieved FedRAMP® High Authorization, the federal government's highly stringent cloud security standard, with the
U.S . Department of Justice (DOJ) serving as the authorizing agency.
Go-To-Market
- Drone Partnership: Last month, Cellebrite announced an expanded partnership with SkySafe, the leader in drone detection and airspace intelligence. The exclusive partnership combines advanced digital forensics with advanced drone detection, deep analysis and drone activity, equipping organizations and agencies with the intelligence needed to proactively detect, analyze and act on potential threats in real-time at scale.
- High-Impact Customer Events: Following a highly successful, second annual user conference in April 2026, Cellebrite hosted a 2-day C2C
UK event on June 16th and 17th. The Company plans to host a range of regional C2C Live events, featuring sessions designed to support learning, collaboration and best practices, for customers inU.S .,Europe andAsia-Pacific during the second half of 2026.
Supplemental financial information can be found on the Investor Relations section of our website at https://investors.cellebrite.com/financial-information/quarterly-results.
Financial Outlook
David Barter, Cellebrite's CFO, said, "Although we didn't deliver against our second-quarter 2026 ARR target, we have continued to make tangible progress in executing Cellebrite's product strategy, with newer products contributing more meaningfully to net new ARR than a year ago, and we expect that momentum to continue into the second half of the year. While we've lowered our full-year ARR expectations, along with the resulting impact on our revenue target, we have raised this year's original adjusted EBITDA target and anticipate delivering a stronger second-half free cash flow performance even as we continue funding the investments critical to driving durable, long-term growth."
The Company's third-quarter and full-year 2026 financial expectations are as follows:
Third-Quarter 2026 Expectations | Full-Year 2026 Expectations | |||
(as of 08/13/26) | (as of 08/13/26) | |||
ARR | ||||
Annual Growth | ||||
Revenue | ||||
Annual Growth | ||||
Adjusted EBITDA | ||||
Adjusted EBITDA margin | ~ |
Conference Call Information
Cellebrite will host a live conference call and webcast later today to review the Company's second-quarter 2026 financial results and discuss its full-year 2026 outlook. Pertinent details include:
Date: | Thursday, August 13, 2026 | |
Time: | 8:30 a.m. ET | |
Call-In Number: | 785-838-9251 / 833-309-3473 | |
Conference ID: | CLBTQ226 | |
Event URL: | ||
Webcast URL: |
In conjunction with the conference call and webcast, historical financial tables and supplemental data will be available on the quarterly results section of Company's investor relations website at https://investors.cellebrite.com/financial-information/quarterly-results.
Non-GAAP Financial Information and Key Performance Indicators
This press release includes non-GAAP financial measures. Cellebrite believes that the use of non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP operating expenses, non-GAAP operating income, non-GAAP net income, non-GAAP EPS and adjusted EBITDA is helpful to investors. These measures, which the Company refers to as its non-GAAP financial measures, are not prepared in accordance with GAAP.
The Company believes that the non-GAAP financial measures provide a more meaningful comparison of its operational performance from period to period, and offer investors and management greater visibility into the underlying performance of its business:
- Share-based compensation expenses utilize varying available valuation methodologies, subjective assumptions and a variety of equity instruments that can impact a company's non-cash expenses;
- Acquired intangible assets are valued at the time of acquisition and are amortized over an estimated useful life after the acquisition;
- Acquisition-related expenses and executive severance expenses relate to the cash component of contractual severance due to our former CFO, all of which are unrelated to current operations and neither are comparable to the prior period nor predictive of future results;
- To the extent that the above adjustments have an effect on tax (income) expense, such an effect is excluded in the non-GAAP adjustment to net income;
- Tax expense, depreciation and amortization expense vary for many reasons that are often unrelated to our underlying performance and make period-to-period comparisons more challenging; and
- Financial instruments are remeasured according to GAAP and vary for many reasons that are often unrelated to the Company's current operations and affect financial income.
Free cash flow is calculated as net cash provided by or used in operating activities less purchases of property and equipment and the capitalization of software development costs (collectively referred to as capital expenditures). We believe that free cash flow is a useful indicator of liquidity that provides information to management and investors about the amount of cash provided by or used in our operations that, after the investments in property and equipment, can be used for strategic initiatives.
Each of our non-GAAP financial measures is an important tool for financial and operational decision making and for evaluating our own operating results over different periods of time. The non-GAAP financial measures do not represent our financial performance under
A reconciliation of each of these non-GAAP financial measures to their most comparable GAAP measure is set forth in a table included at the end of this press release, which is also available on our website at https://investors.cellebrite.com.
In regard to forward-looking non-GAAP guidance, we are not able to reconcile the forward-looking adjusted EBITDA measure to the closest corresponding GAAP measure without unreasonable efforts because we are unable to predict the ultimate outcome of certain significant items including, but not limited to, fair value movements, share-based payments for future awards, tax expense, depreciation and amortization expense, and certain financing and tax items.
This press release also includes key performance indicators, including annual recurring revenue and dollar-based retention rate.
Annual recurring revenue ("ARR") is defined as the value of subscription-based customer agreements encompassing term-based on-premise software and cloud-based software, including those offerings delivered under a recurring consumption-based model, that are in effect at the end of the reporting period. For subscription-based agreements, ARR is calculated as the total contract value of the agreement divided by the length of the agreement, measured as of the end of the period and assuming no increases or reductions to the customer's subscription. For consumption-based cloud software subscriptions, ARR is calculated as the total contract value of the subscription divided by the length of the agreement, assuming no increases or reductions in the customer's usage rate. For new agreements with a term of less than 12 months, ARR is calculated as the total contract value of the agreement, without annualization. The annualized value of contracts is a legal and contractual determination made by assessing the contractual terms with our customers, including contracts for which we are actively negotiating a subscription renewal, which continue to be included in ARR until the customer notifies the Company that it does not intend to renew. ARR is not a forecast of future subscription revenue, which can be impacted by contract start and end dates and renewal rates.
Dollar-based net retention rate ("NRR") is calculated by dividing the customer's ARR by the base ARR. We define base ARR as recurring revenue we recognized from all customers with a valid license at the last quarter of the previous year period, during the four quarters ended one year prior to the date of measurement. We define our customer's ARR as the recurring revenue we recognized during the four quarters ended on the date of measurement from the same customer base included in our measure of base ARR, including recurring revenue resulting from additional sales to those customers.
References to Websites and Social Media Platforms
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.
Caution Regarding Forward Looking Statements
This document includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "will," "appear," "approximate," "foresee," "might," "possible," "potential," "believe," "could," "predict," "should," "could," "continue," "expect," "estimate," "may," "plan," "outlook," "future" and "project" and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include, but are not limited to, estimated financial information for the third quarter of 2026 and for fiscal year 2026 including those statements with respect to our FY26 revenue, revenue and adjusted EBITDA outlook; the expectation for a stronger second-half free cash flow performance even as we continue funding the investments critical to driving durable, long-term growth; and the near-term contribution from new products given elongated sales cycles and the timing of additional new product introductions anticipated for later this year; as well as commentary associated with future performance, strategies, prospects, and other aspects of Cellebrite's business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: Cellebrite's ability to keep pace with technological advances and challenges and evolving industry standards with respect to software, artificial intelligence, or device access, to adapt to changing market potential within our markets and to successfully launch new solutions and add-ons that meet or exceed customer needs; our material dependence on the acceptance of our solutions by domestic and international law enforcement, public safety, defense and intelligence agencies; real or perceived errors, failures, defects or bugs in our solutions; licensing of technology from third parties, including our dependence on maintaining those licenses or seeking alternative solutions; failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of our markets, including risks associated with pricing pressures from and loss of market share to competitors with greater resources than we have and increasing competition as a result of consolidation in the industry; the misuse of our solutions by our customers which may achieve suboptimal results or be perceived as incompatible with human rights; our ability to properly manage our growth as a business, and execute new offerings, developments and strategic opportunities, including joint ventures, partnerships and acquisitions; our dependence on our customers to renew their subscriptions and purchase additional subscriptions or services from us; conducting a low volume of our business via e-commerce; the use of artificial intelligence in our digital investigation platform; the availability of financing sources on reasonable terms or at all; our reliance on third-party suppliers for certain components, products or services, including risks relating to the availability of raw materials or components; challenges associated with large transactions, including with respect to longer sales cycles, as well as with developing, offering, implementing, and maintaining new solutions; risk of security vulnerabilities or defects, including cyber-attacks, information technology system breaches, failures or disruptions which are critical to our operations and maintaining the trust and confidence of our customers; risks associated with political, geo-political and reputational factors related to our business or operations, including Cellebrite operations in
About Cellebrite
Cellebrite's (Nasdaq: CLBT) mission is to protect communities, nations and businesses as a global leader in digital investigative and intelligence solutions. More than 7,000 global law enforcement agencies, defense and intelligence organizations and enterprises trust Cellebrite's AI-powered software portfolio to make forensically sound digital data more accessible and actionable. Cellebrite technology allows customers to accelerate nearly 3 million legally sanctioned investigations annually, enhance sovereign security, elevate operational efficacy and efficiency and enable advanced mobile research and application security. Available via cloud, on-premises and hybrid deployments, Cellebrite's technology enables its customers around the globe to advance their missions, elevate public safety and safeguard data privacy. To learn more, visit us at www.cellebrite.com and https://investors.cellebrite.com and find us on social media @Cellebrite.
Contacts:
Investors Relations
Andrew Kramer
Vice President, Investor Relations & Treasury
investors@cellebrite.com
+1 973.206.7760
Media
Jackie Labrecque
Director, PR and Executive Communications
jackie.labrecque@cellebrite.com
+1 771.241.7010
Cellebrite DI Ltd. | |||||||
For the three months ended | For the six months ended | ||||||
June 30, | June 30, | ||||||
2026 | 2025 | 2026 | 2025 | ||||
Revenue | 131,138 | 113,276 | 259,439 | 220,825 | |||
Gross profit | 105,931 | 95,599 | 211,812 | 185,658 | |||
Gross margin | 80.8 % | 84.4 % | 81.6 % | 84.1 % | |||
Operating income | 6,949 | 14,417 | 16,068 | 26,685 | |||
Operating margin | 5.3 % | 12.7 % | 6.2 % | 12.1 % | |||
Net income | 6,371 | 19,476 | 17,309 | 36,876 | |||
Cash flow from operating activities | 17,589 | 32,583 | 37,474 | 53,461 | |||
Non-GAAP Financial Data: | |||||||
Operating income | 29,805 | 26,224 | 58,391 | 48,195 | |||
Operating margin | 22.7 % | 23.2 % | 22.5 % | 21.8 % | |||
Net income | 29,692 | 30,773 | 60,312 | 56,952 | |||
Adjusted EBITDA | 31,790 | 27,885 | 62,407 | 51,561 | |||
Adjusted EBITDA margin | 24.2 % | 24.6 % | 24.1 % | 23.3 % | |||
Cellebrite DI Ltd. | ||||
June 30, | December 31, | |||
2026 | 2025 | |||
Assets | ||||
Current assets | ||||
Cash and cash equivalents | $ 141,250 | $ 124,457 | ||
Short-term deposits | 146,759 | 161,049 | ||
Marketable securities | 154,522 | 151,544 | ||
Trade receivables (net of allowance for credit losses of | 110,782 | 104,972 | ||
Prepaid expenses and other current assets | 21,514 | 19,630 | ||
Contract acquisition costs | 6,466 | 6,595 | ||
Inventories | 8,388 | 7,603 | ||
Total current assets | 589,681 | 575,850 | ||
Non-current assets | ||||
Other non-current assets | 7,344 | 14,618 | ||
Marketable securities | 103,185 | 97,959 | ||
Deferred tax assets, net | 11,667 | 10,880 | ||
Property and equipment, net | 24,552 | 22,209 | ||
Operating lease right-of-use assets, net | 16,414 | 16,308 | ||
Intangible assets, net | 121,909 | 81,469 | ||
Goodwill | 119,559 | 119,559 | ||
Total non-current assets | 404,630 | 363,002 | ||
Total assets | $ 994,311 | $ 938,852 | ||
Liabilities and shareholders' equity | ||||
Current Liabilities | ||||
Trade payables | $ 18,113 | $ 16,834 | ||
Other accounts payable and accrued expenses | 77,009 | 71,244 | ||
Deferred revenues | 263,350 | 277,583 | ||
Operating lease liabilities | 5,736 | 3,996 | ||
Total current liabilities | 364,208 | 369,657 | ||
Long-term liabilities | ||||
Other long-term liabilities | 24,573 | 16,677 | ||
Deferred revenues | 49,940 | 49,526 | ||
Operating lease liabilities | 17,493 | 18,674 | ||
Total long-term liabilities | 92,006 | 84,877 | ||
Total liabilities | 456,214 | 454,534 | ||
Shareholders' equity | ||||
Share capital | *) | *) | ||
Additional paid-in capital | 605,809 | 568,721 | ||
Treasury share, | (85) | (85) | ||
Accumulated other comprehensive income | 1,602 | 2,220 | ||
Accumulated deficit | (69,229) | (86,538) | ||
Total shareholders' equity | 538,097 | 484,318 | ||
Total liabilities and shareholders' equity | $ 994,311 | $ 938,852 | ||
*) Less than | ||||
Cellebrite DI Ltd. | |||||||
For the three months ended | For the six months ended | ||||||
June 30, | June 30, | ||||||
2026 | 2025 | 2026 | 2025 | ||||
Revenue: | |||||||
Subscription services | $ 97,685 | $ 80,814 | $ 194,234 | $ 157,502 | |||
Term-license | 21,805 | 22,147 | 43,109 | 41,288 | |||
Other non-recurring | 3,912 | 3,292 | 7,580 | 7,703 | |||
Professional services | 7,736 | 7,023 | 14,516 | 14,332 | |||
Total revenue | 131,138 | 113,276 | 259,439 | 220,825 | |||
Cost of revenue: | |||||||
Subscription services | 15,981 | 8,522 | 30,219 | 16,954 | |||
Other non-recurring | 3,764 | 3,198 | 7,261 | 6,499 | |||
Professional services | 5,462 | 5,957 | 10,147 | 11,714 | |||
Total cost of revenue | 25,207 | 17,677 | 47,627 | 35,167 | |||
Gross profit | $ 105,931 | $ 95,599 | $ 211,812 | $ 185,658 | |||
Operating expenses: | |||||||
Research and development, net | 35,961 | 28,611 | 71,833 | 55,888 | |||
Sales and marketing | 43,753 | 38,685 | 86,975 | 77,453 | |||
General and administrative | 19,268 | 13,886 | 36,936 | 25,632 | |||
Total operating expenses | $ 98,982 | $ 81,182 | $ 195,744 | $ 158,973 | |||
Operating income | $ 6,949 | $ 14,417 | $ 16,068 | $ 26,685 | |||
Financial income, net | 4,238 | 6,374 | 8,753 | 13,434 | |||
Income before tax | 11,187 | 20,791 | 24,821 | 40,119 | |||
Tax expense | 4,816 | 1,315 | 7,512 | 3,243 | |||
Net income | $ 6,371 | $ 19,476 | $ 17,309 | $ 36,876 | |||
Earnings per share | |||||||
Basic | $ 0.03 | $ 0.08 | $ 0.07 | $ 0.15 | |||
Diluted | $ 0.02 | $ 0.08 | $ 0.07 | $ 0.15 | |||
Weighted average shares outstanding | |||||||
Basic | 247,617,591 | 240,358,573 | 247,047,007 | 238,811,210 | |||
Diluted | 252,788,652 | 248,980,462 | 252,436,239 | 249,410,357 | |||
Other comprehensive income (loss): | |||||||
Unrealized income (loss) on hedging transactions | 788 | 2,936 | (163) | 2,157 | |||
Unrealized (loss) income on marketable securities | (495) | 39 | (1,314) | 103 | |||
Currency translation adjustments | 317 | (1,226) | 859 | (1,707) | |||
Total other comprehensive income (loss), net of tax | 610 | 1,749 | (618) | 553 | |||
Total other comprehensive income | $ 6,981 | $ 21,225 | $ 16,691 | $ 37,429 | |||
Cellebrite DI Ltd. | ||||||||
For the three months ended | For the six months ended | |||||||
June 30, | June 30, | |||||||
2026 | 2025 | 2026 | 2025 | |||||
Cash flow from operating activities: | ||||||||
Net income | $ 6,371 | $ 19,476 | $ 17,309 | $ 36,876 | ||||
Adjustments to reconcile net income to net cash provided | ||||||||
Share-based compensation and RSU's | 15,249 | 8,810 | 29,633 | 17,587 | ||||
Amortization of premium, accretion of discount and | (237) | (1,202) | (1,385) | (1,725) | ||||
Depreciation and amortization | 8,915 | 2,592 | 15,920 | 5,223 | ||||
Interest income from short-term deposits | (1,736) | (2,303) | (3,529) | (4,683) | ||||
Deferred tax assets, net | (15) | (1,387) | (765) | (1,773) | ||||
Increase in trade receivables | (38,070) | (10,931) | (5,629) | (9,210) | ||||
Increase (decrease) in deferred revenue | 7,987 | 2,310 | (12,874) | 3,302 | ||||
(Increase) decrease in other non-current assets | (253) | 210 | 299 | 995 | ||||
Decrease (increase) in prepaid expenses and other current assets | 4,351 | (2,748) | (613) | 2,732 | ||||
Changes in operating lease right-of-use assets | 1,058 | 1,070 | 2,113 | 2,226 | ||||
Changes in operating lease liability | (645) | (532) | (1,660) | (1,711) | ||||
Increase in inventories | (859) | (524) | (715) | (534) | ||||
Increase (decrease) in trade payables | 7,181 | (166) | 1,194 | (1,212) | ||||
Increase (decrease) in other accounts payable and accrued expenses | 6,898 | 17,622 | (3,495) | 5,470 | ||||
Increase (decrease) in other long-term liabilities | 1,394 | 286 | 1,671 | (102) | ||||
Net cash provided by operating activities | 17,589 | 32,583 | 37,474 | 53,461 | ||||
Cash flows from investing activities: | ||||||||
Capital expenditures | (3,068) | (3,608) | (6,109) | (5,947) | ||||
Cash paid in conjunction with acquisitions, net of acquired cash | — | — | (15,278) | — | ||||
Purchase of Intangible assets | (8,560) | — | (15,619) | — | ||||
Investment in marketable securities | (50,050) | (53,190) | (124,625) | (183,146) | ||||
Proceeds from maturities of marketable securities | 36,338 | 32,204 | 60,945 | 59,623 | ||||
Proceeds from sales of marketable securities | 15,840 | 31,166 | 55,546 | 31,166 | ||||
Investment in short-term deposits | (46,000) | — | (82,000) | (84,000) | ||||
Redemption of short-term deposits | 41,754 | 34,005 | 99,819 | 96,377 | ||||
Net cash (used in) provided by investing activities | (13,746) | 40,577 | (27,321) | (85,927) | ||||
Cash flows from financing activities: | ||||||||
Exercise of options to shares | 2,123 | 12,624 | 4,251 | 15,117 | ||||
Proceeds from Employee Share Purchase Plan | 1,485 | 1,202 | 2,868 | 2,329 | ||||
Net cash provided by financing activities | 3,608 | 13,826 | 7,119 | 17,446 | ||||
Net increase (decrease) in cash and cash equivalents | 7,451 | 86,986 | 17,272 | (15,020) | ||||
Net effect of Currency Translation on cash and cash equivalents | 110 | 1,762 | (479) | 2,584 | ||||
Cash and cash equivalents at beginning of period | 133,689 | 90,475 | 124,457 | 191,659 | ||||
Cash and cash equivalents at end of period | $ 141,250 | $ 179,223 | $ 141,250 | $ 179,223 | ||||
Supplemental cash flow information: | ||||||||
Income taxes paid (received) | $ 6,997 | $ (8,879) | $ 10,535 | $ (8,073) | ||||
Non-cash activities | ||||||||
Operating lease liabilities arising from obtaining right-of-use assets | $ 1,069 | $ 12,328 | $ 2,219 | $ 13,141 | ||||
Cellebrite DI Ltd. | |||||||
For the three months ended | For the six months ended | ||||||
June 30, | June 30, | ||||||
2026 | 2025 | 2026 | 2025 | ||||
(Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | ||||
Cost of revenue | $ 25,207 | $ 17,677 | $ 47,627 | $ 35,167 | |||
Less: | |||||||
Share-based compensation | 657 | 827 | 1,349 | 1,577 | |||
Amortization of intangible assets | 5,536 | — | 9,148 | — | |||
Acquisition-related costs | 1 | — | 1 | — | |||
Non-GAAP cost of revenue | $ 19,013 | $ 16,850 | $ 37,129 | $ 33,590 | |||
For the three months ended | For the six months ended | ||||||
June 30, | June 30, | ||||||
2026 | 2025 | 2026 | 2025 | ||||
(Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | ||||
Gross profit | $ 105,931 | $ 95,599 | $ 211,812 | $ 185,658 | |||
Share-based compensation | 657 | 827 | 1,349 | 1,577 | |||
Amortization of intangible assets | 5,536 | — | 9,148 | — | |||
Acquisition-related costs | 1 | — | 1 | — | |||
Non-GAAP gross profit | $ 112,125 | $ 96,426 | $ 222,310 | $ 187,235 | |||
For the three months ended | For the six months ended | ||||||
June 30, | June 30, | ||||||
2026 | 2025 | 2026 | 2025 | ||||
(Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | ||||
Operating expenses | $ 98,982 | $ 81,182 | $ 195,744 | $ 158,973 | |||
Less: | |||||||
Share-based compensation | 14,592 | 7,983 | 28,284 | 16,010 | |||
Amortization of intangible assets | 1,394 | 931 | 2,756 | 1,857 | |||
Acquisition-related costs | 676 | 2,066 | 785 | 2,066 | |||
Non-GAAP operating expenses | $ 82,320 | $ 70,202 | $ 163,919 | $ 139,040 | |||
For the three months ended | For the six months ended | ||||||
June 30, | June 30, | ||||||
2026 | 2025 | 2026 | 2025 | ||||
(Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | ||||
Operating income | $ 6,949 | $ 14,417 | $ 16,068 | $ 26,685 | |||
Share-based compensation | 15,249 | 8,810 | 29,633 | 17,587 | |||
Amortization of intangible assets | 6,930 | 931 | 11,904 | 1,857 | |||
Acquisition-related costs | 677 | 2,066 | 786 | 2,066 | |||
Non-GAAP operating income | $ 29,805 | $ 26,224 | $ 58,391 | $ 48,195 | |||
Cellebrite DI Ltd. | |||||||
For the three months ended | For the six months ended | ||||||
June 30, | June 30, | ||||||
2026 | 2025 | 2026 | 2025 | ||||
(Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | ||||
Net income | $ 6,371 | $ 19,476 | $ 17,309 | $ 36,876 | |||
Share-based compensation | 15,249 | 8,810 | 29,633 | 17,587 | |||
Amortization of intangible assets | 6,930 | 931 | 11,904 | 1,857 | |||
Acquisition-related costs | 677 | 2,066 | 786 | 2,066 | |||
Tax expense (income) | 465 | (510) | 680 | (1,434) | |||
Non-GAAP net income | $ 29,692 | $ 30,773 | $ 60,312 | $ 56,952 | |||
Non-GAAP Earnings per share: | |||||||
Basic | $ 0.12 | $ 0.13 | $ 0.24 | $ 0.24 | |||
Diluted | $ 0.11 | $ 0.12 | $ 0.23 | $ 0.22 | |||
Weighted average shares outstanding: | |||||||
Basic | 247,617,591 | 240,358,573 | 247,047,007 | 238,811,210 | |||
Diluted | 259,522,205 | 252,713,944 | 259,390,445 | 252,618,208 | |||
For the three months ended | For the six months ended | ||||||
June 30, | June 30, | ||||||
2026 | 2025 | 2026 | 2025 | ||||
(Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | ||||
Net income | $ 6,371 | $ 19,476 | $ 17,309 | $ 36,876 | |||
Financial income, net | (4,238) | (6,374) | (8,753) | (13,434) | |||
Tax expense | 4,816 | 1,315 | 7,512 | 3,243 | |||
Share-based compensation | 15,249 | 8,810 | 29,633 | 17,587 | |||
Amortization of intangible assets | 6,930 | 931 | 11,904 | 1,857 | |||
Acquisition-related costs | 677 | 2,066 | 786 | 2,066 | |||
Depreciation expenses | 1,985 | 1,661 | 4,016 | 3,366 | |||
Adjusted EBITDA | $ 31,790 | $ 27,885 | $ 62,407 | $ 51,561 | |||
For the three months ended | For the six months ended | ||||||
June 30, | June 30, | ||||||
2026 | 2025 | 2026 | 2025 | ||||
(Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | ||||
Net cash provided by operating activities | $ 17,589 | $ 32,583 | $ 37,474 | $ 53,461 | |||
Less: | |||||||
Capital expenditures | (3,068) | (3,608) | (6,109) | (5,947) | |||
Free cash flow | $ 14,521 | $ 28,975 | $ 31,365 | $ 47,514 | |||
Free cash flow margin | 11.1 % | 25.6 % | 12.1 % | 21.5 % | |||
Cellebrite DI Ltd. | |||||||||
For the trailing | For the three months ended | ||||||||
June 30, | June 30, | March 31, | December 31, | September 30, | |||||
2026 | 2026 | 2026 | 2025 | 2025 | |||||
(Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |||||
Net cash provided by operating activities | $ 157,557 | $ 17,589 | $ 19,885 | $ 86,811 | $ 33,272 | ||||
Less: | |||||||||
Capital expenditures | (13,387) | (3,068) | (3,041) | (3,956) | (3,322) | ||||
Free cash flow | $ 144,170 | $ 14,521 | $ 16,844 | $ 82,855 | $ 29,950 | ||||
Free cash flow margin | 28.0 % | 11.1 % | 13.1 % | 64.3 % | 23.8 % | ||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/cellebrite-appoints-shiven-ramji-chief-executive-officer-succeeding-thomas-e-hogan-302850249.html
SOURCE Cellebrite